Switch to dolutegravir/lamivudine (DTG/3TC) in people living with HIV-1 suppressed on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): 96-week final analysis from the SOUND study

Dr Jihad Slim is Chief of Infectious Diseases at Saint Michael’s Medical Center in Newark, NJ, and Assistant Professor of Medicine at New York Medical College in Valhalla, NY. Dr Slim’s clinical research interests include antibiotic stewardship, HIV, hepatitis C, and COVID-19.